Stop TB Partnership

Documents & Reports

Annual Reports

GDF Activity Report 2012-2013
October 2014

Stop TB Partnership - Global Drug Facility Annual Report 2011 [.pdf]

Stop TB Partnership - Global Drug Facility Annual Report 2010 [.pdf]

QA Report

Global Drug Facility QA Report - 2011 [.pdf]


Impact of Donor Support on TB Pharmaceutical Systems [.pdf]

GDF second-line drug regimen cost comparison - March 2013 [.pdf]

Report of TB Drug Manufacturers Meeting Aug 29-30 2011 [.pdf]

"How the challenges of accessing anti-TB treatment are being confronted" Public Service Review: International Development Issue 14; June 2009 [.pdf]

WHO Technical Briefing Note to Switch to New Paediatric TB Formulations

Marking up the Medicines [.pdf]
A look at GDF’s contribution towards universal access to high-quality anti TB medicines and how the public health community can tackle the manifold quality, price and access challenges that lie ahead in the fight against drug-sensitive and multidrug-resistant TB.

Rationale for standardizing TB drugs [.pdf]
A look at the advantages for TB programmes of the use of standardized anti-TB drugs

10in6 [.pdf]
The Global Drug Facility (GDF) has provided 10 million life-saving anti-TB drug treatments in its first six years of operation and is on track to supply 25 million treatments by 2015.

WHO bulletin article on GDF from 2007 [.pdf]
The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management.

GDF's Comparative Advantages [.pdf]
An overview of the range of products and services provided by GDF.

GDF's Direct Procurement Service [.pdf]
An overview of GDF’s comprehensive Direct Procurement Service

GDF Suppliers: Access and Opportunity [.pdf]
An overview for anti-TB drug manufacturers of the benefits of working with GDF.

Direct Procurement Brochure [.pdf] | Spanish [.pdf] | French [.pdf]
A guide to the GDF Direct Procurement Service for donors, non-governmental organizations and programme managers

Sustaining the Gains [.pdf] | French [.pdf]
The GDF Sustaining the Gains Strategy describes how the GDF encourages countries to take increasing responsibility to fund their TB control programmes while maintaining uninterrupted access to standardized, quality and competitively priced anti-TB drugs -- thus ensuring that any "gains" made through GDF grants are secured.

The Global TB Drug Facility: innovative global procurement[.pdf]
This paper describes the GDF operational procedures and experience gained so far. Key achievements to date are also outlined, including the creation of a flexible supply system to meet differing programme needs, rapid establishment of procedures, reduction in TB drug prices—a catalyst for DOTS expansion in countries, standardisation of products, and collaboration with partners.

Operational Guide for National Tuberculosis Control Programmes on the Introduction and Use of Fixed-Dose Combination Drugs [.pdf] | French [.pdf]
[WHO/CDS/TB/2002.308 - WHO/EDM/PAR/2002.6]
WHO has recently published this publication. Both WHO and The Union recommend the use of fixed-dose combination (FDC) drugs to prevent monotherapy and reduce the risk of drug resistance. This guide will assist NTP managers and their TB partners to understand underlying issues in drug management related to switching to FDCs, i.e. quantifying drug needs, assuring quality, stock management, and use. One chapter is solely devoted to how to changeover to FDCs.

Improving TB Drug Management - Accelerating DOTS Expansion [.pdf]
The incidence of tuberculosis (TB) is increasing in many parts of the world, and partner organizations of Stop TB recognize the significant role drug management plays in ensuring that safe, effective, quality drugs are available when and where patients need them.
The main objective of the survey discussed in this paper was to identify specific problems in connection with drug management and availability of drugs for treating tuberculosis (TB) at the central and peripheral levels in two developing countries, Republic of Congo and India (the state of Uttar Pradesh).

Frequently asked questions: about the 4 drug fixed-dose combination tablet recommended by WHO [.pdf]
The majority of tuberculosis patients worldwide are still treated with single drugs, or with 2-drug fixed-dose combinations (FDCs). To improve tuberculosis treatment, 2- and 3-drug FDCs were recommended by the World Health Organization (WHO) as part of the DOTS strategy. Recently, however, a 4-drug FDC containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol was added to the WHO Model List of Essential Drugs, which made possible an intensive-phase treatment for tuberculosis based fully on an FDC. This document is intended to answer frequently asked questions about the recently introduced 4-drug FDC, but many of the issues are also relevant to the 2- and 3-drug FDCs.

GDF Rationale for Standardisation [.pdf]

Fact Sheets (Oct'01) [.pdf]
Future generations will no doubt ask us why we continued to allow two million people to die every year from a disease that can be cured with drugs that cost only US$ 10. They will rightly question our commitment, our priorities, our sense of justice, and our understanding of human rights.

The establishment of the Global TB Drug Facility (GDF) is one of the most important activities of the Stop TB Initiative. In March 2000, Ministers of Health, Finance and Development Planning from twenty of the highest TB burden countries endorsed the "Amsterdam Declaration to Stop TB", committing themselves to reaching global DOTS targets by 2005 and calling upon international partners to increase their support to "new international approaches towards ensuring universal access to and efficient national systems for procurement and distribution of tuberculosis drugs."


GDF is ISO 9001:2000 compliant for provision of quality-assured anti-TB drugs and related services to eligible national TB control programmes.